Ryan Scott

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced gastrointestinal NETs.

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive grade 1 or grade 2 GEP-NETs.

BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with chemo, fewer were reported.

In the LEAP-015 trial, Keytruda and Lenvima plus chemo did not meet the primary end point of overall survival in HER2– gastroesophageal adenocarcinoma.

Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with myelodysplastic syndrome.

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The first participant has been dosed on the phase 2 CONVERGE study evaluating NBTXR3 in stage III, unresectable non–small cell lung cancer.

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors.

Dr. Anna Arthur discusses how the NOURISH trial is addressing food insecurity and malnutrition in patients undergoing treatment for their blood cancers.

Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a second-line therapy.

Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors.

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer.

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome prior to alloHSCT.

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.

Dr. Ritu Salani discussed Cervical Cancer Awareness Month, highlighting what patients with this disease should be aware of as well as prevention tactics.

Dr. Christopher Flowers discusses MRD testing in cancer care, why this is an important concept to understand and how it relates to recurrence in patients.

Yescarta continued to demonstrate durable responses after a median follow-up of more than five years in patients with R/R indolent non-Hodgkin lymphoma.

Patients with lymphoma or leukemia with methotrexate-induced acute kidney injury experienced improved renal outcomes following glucarpidase treatment.

Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means for those with solid tumors.

Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.

Dr. Maxwell Lloyd shared the importance of improving patient access to innovative therapies like Orserdu at the 2024 San Antonio Breast Cancer Symposium.

Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients with various types of cancer.

In patients with cancer, HT-001, designed to address skin toxicities, elicited encouraging interim safety and efficacy results in the CLEER-001 trial

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient access, according to experts.

Indicators for Gleevec nonadherence were cognitive functioning, global health status score, social support, gender and others in patients with GIST.

Dr. Aditya Bardia shared his insights on what he believes are the top side effects to be aware of when undergoing ADC treatment for breast cancer.